Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial

Area of Science:

• Neuroscience
• Clinical Pharmacology
• Genetics

Background:

• Fragile X syndrome (FXS) is a genetic disorder causing intellectual disability and developmental challenges.
• Current treatments for FXS primarily manage symptoms, with limited options for addressing the underlying pathology.
• Ampakines, like CX516, modulate AMPA receptors, which are implicated in learning and memory and may play a role in FXS.

Purpose of the Study:

• To evaluate the safety and efficacy of the Ampakine compound CX516 as a potential treatment for FXS.
• To assess the impact of CX516 on cognitive, behavioral, and functional outcomes in adults with FXS.
• To identify reliable outcome measures for future clinical trials in the FXS population.

Main Methods:

• A Phase II, 4-week, randomized, double-blind, placebo-controlled trial involving 49 adult subjects with FXS.
• Subjects received either CX516 or a placebo after a 1-week placebo lead-in period.
• Cognitive and behavioral assessments were conducted at baseline, end of treatment, and 2 weeks post-treatment.

Main Results:

• CX516 was generally well-tolerated with minimal side effects, though 12.5% experienced allergic rash.
• No significant improvements were observed in memory, language, attention, behavior, or overall functioning compared to placebo.
• The study successfully demonstrated the reproducibility of several outcome measures in the FXS population for future trials.

Conclusions:

• CX516 did not show efficacy in improving cognitive or behavioral deficits in adults with FXS within the study parameters.
• Potential issues with CX516 potency or inadequate dosing may have limited therapeutic effects.
• Further investigation is required to ascertain if targeting AMPA-mediated neurotransmission is a viable therapeutic strategy for FXS.